Donald E. Nickelson joined the Cross Match Board of Directors as Chairman in May 2008. He is currently the Vice-Chairman and Director of Harbour Group Industries Inc., a leveraged buy-out firm. Mr. Nickelson also serves as Chairman of the Board of Advisors for Celtic Therapeutics, a Director of Adolor Corporation and is a member of the Advisory Board of Celtic Pharmaceutical Holdings, L.P. In addition, he serves on the boards of several private companies.

Previously, Mr. Nickelson was President of PaineWebber Group, an investment banking and brokerage firm, and acted as Lead Trustee of the Mainstay Mutual Funds Group. He also served as the Chairman of the Board of Omniquip International, Inc., Greenfield Industries, Vie Financial Group and Flair Corporation. As a director, Mr. Nickelson served on the boards for W. P. Carey & Co., LLC, Royalty Pharma AG, Allied Healthcare Products, DT Industries, as well as biotech companies Selectide Corporation and Sugen, Inc. Additionally, he served as Chairman of the Pacific Stock Exchange and Director of the Chicago Board Options Exchange.

John Langston has served as a Director since April 2008. Since December 2000 he has served as a Director of Smiths Group plc. A Chartered Accountant, Mr. Langston was appointed Finance Director of Smiths Group plc in September 2006. Mr. Langston has held various senior management positions within Smiths Group, including Group Managing Director -- Specialty Engineering, Group Managing Director – Detection and head of Sealing Solutions.

Mr. Langston had been a director of TI Group plc since October 1998. He joined TI Group in 1993, becoming Chief Executive of Bundy Automotive in 1996 and Chief Executive of TI Specialty Polymer Products in 1998. He formerly worked for Lucas Industries.

David Taylor has an extensive background in real estate and financial services. With over 40 years of experience in these disciplines he is currently the Broker/Owner of a commercial real estate company and an upscale residential real estate company. Mr. Taylor is currently the Treasurer of the Flagler County Association of Realtors and Vice President of Finance for the Central Florida Commercial Association of Realtors, and a partner in the Florida Commercial Brokers Network.

Mr. Taylor is also President of his own investment firm that manages his personal investments in real estate, securities, currencies and commodities. He previously was the Chief Financial Officer for Federated Investors, Inc., a $250 billion investment management company that he helped take public in the mid-1990's. At Federated, he was also Executive Vice President of Sales and Marketing before retiring at the end of 2001 and moving to Florida.

Chris Roberts joined the Cross Match Board of Directors in May 2011. As General Counsel at Smiths Detection, he is a member of the Smiths Detection Divisional Board, with functional responsibility for commercial legal affairs, intellectual property and compliance. Mr. Roberts holds degrees from Cambridge University (social anthropology) and Warwick University (law), where he qualified first as a solicitor in England and subsequently as an attorney in New York. He worked for London-based international commercial law firm Slaughter and May for seven years, which included assignments in Hong Kong and Brussels. Mr. Roberts then joined IBM’s (NYSE) EMEA law department, followed by 5 years in the Netherlands with Sybase Inc. (NYSE) leading EMEA legal affairs.

Mr. Roberts returned to the U.K. to join Reckitt Benckiser (FTSE) as its Group General Counsel for four years, after which he established his own business providing executive legal services to the international outdoor division of CBS Corporation and FirstGroup plc. Mr. Roberts joined Smiths Detection in September 2010.

Robert Strang began his law enforcement career in 1979 with the Federal Bureau of Investigation in Washington, D.C. From 1980 to 1989 Mr. Strang was a Special Agent with the Drug Enforcement Administration, distinguishing himself on numerous occasions with the U.S. Department of Justice and the U.S. Attorney's Office.

Mr. Strang co-founded Stang Hayes in 1989, which grew into a leading corporate security firm. Strang Hayes was sold to SPX Corporation (NYSE) in 2001. In 2003, Mr. Strang again collaborated to form Investigative Management Group where he continues to manage a number of complex global investigations involving proxy fights, due diligence investigations, litigation, hostile threats, bankruptcies and a range of other business challenges.

Mr. Strang serves on the Board of Directors for The Brink's Company (NYSE), and is also active with numerous other organizations, including: U.AC.T. Task Force (Unified Against the Challenges of Terrorism); The New York City Civil Service Screening Committee; and D.A.R.E. America and its Executive Committee.

Previously, Mr. Strang was a member of Mayor Rudolph Giuliani's transition team, serving as Chairman of the Drug Enforcement, Treatment & Prevention Taskforce and was an advisor to Giuliani’s Presidential Anti-Terrorism Advisory Board. He also has served as a consultant to the New York State Senate, advising the Investigative Committee, and was Co-Chair of the post 9/11 Anti­ Terrorism Task Force.

Bruce Foerster has a long history in the financial services industry, having spent over 20 years with five different Wall Street firms (Birr, Wilson; H.C. Wainwright; Warburg Paribas Becker/A.G. Becker; PaineWebber; and Lehman Brothers) in increasingly senior positions in equity and fixed income syndicate/capital markets. He was also active in industry affairs, including stints as chairman of both the Securities Industry Association’s (SIA - now Securities Industry Financial Markets Association - SIFMA) Syndicate Committee and the National Association of Securities Dealers’ (NASD - now Financial Industry Regulatory Authority - FINRA) Corporate Financing Committee. Mr. Foerster is also the founding chairman of the SIA New York District Economic Education Foundation.

In 1995, Mr. Foester founded South Beach Capital Markets Advisory Corporation in Miami Beach, Florida as a corporate financial advisory firm, and later merged the business with a Milwaukee broker-dealer. Following two years with Aurora Capital, Inc. as Chief Financial Officer, he re-activated his independent corporate financial advisory business - South Beach Capital Markets Advisory Corporation in 2006.

Mr. Foerster is a frequent lecturer on topics impacting the financial services and investment banking industries, writer of and contributor to industry publications, as well as a teacher and mentor to graduate students at the University of Florida’s Warrington College of Business Administration, Hough Graduate School of Business. Mr. Foerster is a graduate of Haverford College and holds an M.B.A. in Management Information and Control from the University of Pennsylvania’s Wharton School. He spent seven years on active duty as a commissioned officer in the U.S. Navy and a further 20 years in the Naval Reserve, retiring as a Captain.

Jerry Zionic has served as Director since February 2009. He held several positions within Lockheed Martin including Vice President, New Business Ventures and Vice President for Advanced Programs. Mr. Zionic managed the integration of a U.K. acquisition, INSYS, into Lockheed Martin, while serving as the interim Managing Director. Prior to his move to the U.K., Mr. Zionic was President at Lockheed Martin Simulation, Training and Support--a $1B operating element of the corporation's Electronic Systems Business Area. While at Martin Marietta Corporation (MMC) in the 1990s, Mr. Zionic was responsible for new business pursuits and identified the criminal justice market as a focus for corporate growth. He spearheaded MMC's involvement in the national Integrated Automated Fingerprint Identification System (IAFIS), an automated fingerprint identification and criminal history system maintained by the Federal Bureau of Investigation (FBI). Once completed, Mr. Zionic leveraged the success to secure MMC's management of the FBI's Card Scanning Services (CCS) program.
Before joining the private sector, Mr. Zionic completed more than 11 years of active duty with the United States Air Force (USAF). After his tenure with USAF Special Projects, Mr. Zionic held a civil service position at the Pentagon in the Office of the Assistant Secretary of Defense for Intelligence. Mr. Zionic is a graduate of the United States Air Force Academy. He earned two Masters of Science degrees for Aerospace Engineering and Information/Control Engineering from the University of Michigan.

Stephen Evans-Freke joined the Cross Match Board of Directors in April 2009 and had previously served as a director from 2001 to 2004. He is currently Co-Founder and Managing General Partner of Celtic Therapeutics and Co-Founder and Managing Principal of Celtic Pharma, both global private equity funds focused on the pharmaceutical industry. Mr. Evans-Freke has been associated with the biotechnology industry for over 24 years, as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, AMGEN, Centocor, and a number of other leading biotech companies, structured and placed over $500 million of highly successful R&D partnership financing, and served on the Development Boards of these companies. During this period, Mr. Evans-Freke was President of PaineWebber Development Corporation and later a member of PaineWebber Inc.'s Board of Directors. In 1990 Mr. Evans-Freke left Wall Street and founded Selectide Corporation, one of the first combinatorial chemistry companies, for which he served as Chairman until its sale to Heochst in 1994. In 1991, Mr. Evans-Freke founded SUGEN, a drug discovery company focused on small molecule kinase and phosphatase inhibitors; he served as SUGEN Chairman and Chief Executive Officer through its IPO with Morgan Stanley in 1995 and until its sale to Pharmacia for $720 million in 1999. During this time, Mr. Evans-Freke was also a co-founder of Fibrogen, Inc. and Royalty Pharma AG. Mr. Evans-Freke served as an advisor to Pharmacia CEO Fred Hassan until 2001 and devoted himself to his personal venture investments until the founding of Celtic Pharma in 2004.

Mr. Evans-Freke currently serves on the Boards of Cibus Genetics (Chairman), and International BioScience Managers, Ltd. He also serves on the 800-Year Anniversary Appeal Board of Cambridge University, from which he holds a degree in Law; the Cambridge Stem Cell Board; the Board of Governors of the U.S. Priory of the Order of St. John; and the Board of the Christopher and Dana Reeve Foundation. Mr. Evans-Freke is a citizen of the U.K. and Ireland and has been a resident of the U.S. for 28 years.

Dr. Brian Boso joined the Cross Match Board of Directors in May 2011. He is currently the Chief Scientist for Smiths Detection and is Co-Leader of the Divisional Technology Team responsible for all research and development activities. Dr. Boso was previously Chief Technology Officer for the Global Military and Emergency Responders group. He joined Smiths Detection in August 2003, having previously held the positions of Vice-President of Research and Development at Scientific-Atlanta, Inc. and Vice-President of Technology at Tektronix, Inc.
During his career, Dr. Boso has held positions in technology/research and development management, basic/applied research, product/process development, marketing/sales management and manufacturing. He graduated from the University of Illinois with a Ph.D. in Physics and held a postdoctoral position at the Pennsylvania State University.